MedTrace Logo

Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

NCT01306929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.

Conditions

  • Huntington Disease

Interventions

DRUG

pridopidine

45mg bid

Sponsors & Collaborators

  • Prilenia

    lead INDUSTRY

Principal Investigators

  • See Central Contact section for questions about · study officials

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-24
Primary Completion
2018-01-05
Completion
2018-01-05
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306929 on ClinicalTrials.gov